Human papilloma virus immunisation

5 clinical trials

Quick filters

Clinical trials for Human papilloma virus immunisation

5 trials across Europe

See all trials →

Quick filters

5 Clinical trials

Human papilloma virus immunisation

Recruiting

Registered drugNo placebo

A study on the long-term effectiveness and safety of nine-valent human papillomavirus vaccine in women aged 16 to 26 years for prevention of cervical cancer

Registered drugNo placebo

Denmark

Participants:18–64 years · Healthy volunteers
Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Human papilloma virus immunisation

Recruiting

Registered drugNo placebo

Study on the Effectiveness of the Nonavalent HPV Vaccine in Treating Hard-to-Treat Palmar or Plantar Warts in Patients Who Have Not Responded to Two Previous Treatments

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Sodium Chloride
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Human papilloma virus immunisation+1

Recruiting

Registered drug

Study on HPV Vaccine for Women with Vulvar HSIL: Evaluating the Effectiveness of Nonavalent HPV Vaccine in Preventing Recurrence of Vulvar High-Grade Lesions

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Human papilloma virus immunisation

Not recruiting

Registered drugNo placebo

Study on the Safety and Immune Response of 9vHPV Vaccine in Preventing HPV in Boys and Girls Aged 9-14 Compared to Young Women Aged 16-26

Registered drugNo placebo

Poland

Participants:0–17 years · 18–64 years · Healthy volunteers
Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Human papilloma virus immunisation

Not recruiting

Registered drugNo placebo

Study on the Effectiveness of the 9-Valent HPV Vaccine in Children and Adolescents with Weakened Immune Systems

Registered drugNo placebo

Spain

Participants:0–17 years · Healthy volunteers
Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
Sponsor:Hospital Universitario La Paz

Contact Research Centre

See all trials →

Human papilloma virus immunisation

Clinical trials for Human papilloma virus immunisation

Human papilloma virus immunisation

A study on the long-term effectiveness and safety of nine-valent human papillomavirus vaccine in women aged 16 to 26 years for prevention of cervical cancer

Human papilloma virus immunisation

Study on the Effectiveness of the Nonavalent HPV Vaccine in Treating Hard-to-Treat Palmar or Plantar Warts in Patients Who Have Not Responded to Two Previous Treatments

Human papilloma virus immunisation+1

Study on HPV Vaccine for Women with Vulvar HSIL: Evaluating the Effectiveness of Nonavalent HPV Vaccine in Preventing Recurrence of Vulvar High-Grade Lesions

Human papilloma virus immunisation

Study on the Safety and Immune Response of 9vHPV Vaccine in Preventing HPV in Boys and Girls Aged 9-14 Compared to Young Women Aged 16-26

Human papilloma virus immunisation

Study on the Effectiveness of the 9-Valent HPV Vaccine in Children and Adolescents with Weakened Immune Systems

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.